The latest issue of Cryo Letters has details of a report on a new technique for long term storage of human cartilage. Alasdair Kay, lead author - shown in our photo - has been working with a novel vitrification machine, that we are pioneering, which was developed for Prof David Pegg of the University of York. Alasdair is using it at the Tissue Services laboratory in the NHS Blood and Transplant research section at Speke, Liverpool. In his paper, which was presented recently at a meeting of the Society for Low Temperature Biology, he points out that standard cryopreservation techniques give poor post-thaw functional cell survival rates due to extracellular and intracellular crystallisation of ice in the chondrons. This impacts the ability to store transplant material, although the need is potentially very large with some 60,000 knee replacements performed in the UK every year. Currently allograft material can be stored 3 to 4 weeks but transplants are restricted by availability of donor tissue, as cryoprotectant toxicity limits successful cryo preservation. However, the paper (co authored with Messrs Budarina, Grindley, Pegg, Kearney and Rooney) gives early positive indications that a new controlled vitrification process may work. The aim is to achieve the long-term banking of whole femoral condyles from deceased donor human knee joints and to provide them as living allografts to surgeons on demand.
In the process, increasing concentrations of cryoprotectant are supplied during cooling, sufficient to prevent freezing. Toxicity is minimised, by supplying only the concentration required to inhibit crystallisation at the actual temperature reached. This ‘liquidus tracking’ technique builds on a procedure that was highly effective at maintaining cell functionality levels at 75 – 95% in ovine articular cartilage; dimethyl sulphoxide (Me2SO) is applied to femoral condyles in progressively increasing concentrations, whilst tissue is cooled to ultra-low temperatures. Data was collected in this case to ascertain the kinetics of cryoprotective agents (CPA) transport into whole femoral condyles. Measurements of tissue CPAs were progressively taken from 0°C to -80°C and the cryo protectant concentration adjustments were made to ensure sufficient cryoprotectant was present to protect the tissue from ice formation. A reversed two stage warming procedure and structural and functional testing is currently underway to ensure the tissue is not affected by these processes.
See the report at http://www.cryoletters.org/Abstracts/Abstracts_34_2_SLTB_2012.pdf
In Berlin, at the recent Cryo 2013 symposium, one of our smallest Controlled Rate Freezers was on display. The freezer - suitable for vials and straws - was demonstrated on the Origio GmbH stand - our distributors for IVF freezers in Germany.
Our larger range of freezers, used for Stem Cells, Blood, Bone Marrow and in the pharma industry, are supplied through Cryotherm who were also showing the new BT37 Benchtop Incubator and DATAcentre. Our BT37 has become very popular (as well as in human IVF) in the stem cells, animal IVF and transgenic fields. The DATAcentre is a Wireless Monitoring and Alarm system which can be used to monitor all types of equipment and environments including large liquid nitrogen tanks, small aluminium LN2 dewars, incubators and heated stages. It can help measure many parameters as well as Temperature, including Carbon Dioxide, Oxygen, Flow, Level, Differential Pressure and events such as equipment door openings. The distributor for the DATAcentre within the IVF market is Gynemed
Our photo shows the President of France, Francois Hollande, announcing a new initiative which involves our customers Professor Colin McGuckin and Dr Nico Forraz.
Their company CTI Biotech specialises in research into cell therapy and regenerative medicine. It was founded by Colin and Nico, who have used our controlled rate freezers in France and in England.
President Hollande visited Dijon on the 11th of March and announced the launch of Project IMODI . It will receive 13.4 million euros investment under the Futures programme. IMODI stands for "Innovative Models Initiative" and it aims to create the first national network dedicated to personalised medicine in oncology. The project includes large companies such as Sanofi, four SMEs including CTI along with key academic institutions.
CTI 's mission in this is cell model development and they will install (at Meyzieu near Lyon) a national biobank for over 40,000 samples - available to all the project partners. Mr Francois Hollande who met Professor McGuckin and Dr Forraz, came to meet the participants for this enterprise which will hopefully produce tomorrow's drugs to treat cancer and other diseases.
European Group for Blood and Marrow Transplantation 2013
Visit Planer at EBMT 2013 stand 403 on 7-10th April in London, UK at the Excel International Convention Centre
We will be exhibiting and showing our new DATAcentre Monitoring & Alarm System, Controlled Rate Freezers and the ShipsLog Temperature Data Logger for Vapour Shippers as well as our new ReAssure monitoring and alarm system
You can find more information at the show here: http://www.congrex.ch/ebmt2013